浸入科技 IMMR 深 沪
等待开盘 09-18 09:30:00 美东时间
7.10
+0.010
+0.14%
华盛通- 最 高7.23
- 今 开7.06
- 成交量 76.32万股
- 最 低 7.045
- 昨 收 7.09
- 总市值 2.30亿
- 52周最高 10.385
- 市盈率 静 6.80
- 换手率 2.36%
- 52周最低 6.38
- 委 比 -44.24%
- 总股本 3239.64万
- 历史最高 16.97
- 量 比 2.22
- 振 幅 2.61%
- 历史最低 3.415
- 每 手 1
- 风险率 1.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
<p>Immuneering Corporation announced the appointment of Thomas J. Schall, Ph.D., as Chairman of its Board of Directors. Dr. Schall, a seasoned biotech executive and scientist with over 30 years of experience, is known for founding ChemoCentryx and leading the development of Tavneos, which was approved by the FDA and led to the company's acquisition by Amgen for nearly $4 billion. His expertise is expected to strengthen Immuneering's progress in a...
09-16 11:00
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
<p>Immuneering Corporation plans to announce updated overall survival data for first-line pancreatic cancer patients treated with atebimetinib + mGnP on September 25, 2025, during an investor call at 8 a.m. ET. The company will also present this data at the PanCAN Scientific Summit on September 28 and review preclinical data on Deep Cyclic Inhibitors at the RAS-Targeted Drug Development Summit on September 17. Ben Zeskind, CEO, highlighted the si...
09-10 11:00
Immersion Corp. Board Declares Prior Quarterly Financial Statements For 2024-2025 Non-Reliable Due To Barnes & Noble Education Sales And Cost Accounting Issues
On September 8, 2025, the Board of Directors (the "Board") of Immersion Corporation (the "Company") concluded that the Company's previously-issued unaudited interim condensed consolidated financial statements for the
09-09 20:57
Immuneering Announces Closing of $25 Million Private Placement
<p>Immuneering Corporation announced the closing of a $25 million private placement to institutional and accredited investors. Proceeds will support the development of its cancer treatments, including a Phase 2a trial for its lead candidate, atebimetinib. Leerink Partners acted as financial advisor.</p>
08-26 20:05
Immersion Faces Nasdaq Filing Compliance Deadline
The latest update is out from Immersion ( ($IMMR) ). On August 20, 2025, Immers...
08-23 04:48
Immersion Corporation receives delinquency compliance alert notice from Nasdaq
Immersion Corporation (NASDAQ:IMMR) has received a delinquency compliance alert notice from Nasdaq notifying the company that due to the its failure to timely file its annual report on Form 10-K for t...
08-23 04:07
Immersion Announces Quarterly Cash Dividend Declaration
Immersion ( ($IMMR) ) has provided an announcement. On July 8, 2025, Immersion ...
07-09 04:56
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
Immuneering Corporation reported positive Phase 2a data for atebimetinib in combination with modified Gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The treatment showed 94% overall survival (OS) and 72% progression-free survival (PFS) at 6 months, with a 39% overall response rate and 81% disease control rate. Atebimetinib demonstrated a favorable tolerability profile. The company plans a pivotal trial for 2026 and will host...
06-17 10:00
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
<p>Immuneering Corporation announced it will host a conference call and live webcast on June 17, 2025, at 8:00 am ET, to update on its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The webcast will be available on the company's Investor Relations website. IMM-1-104 is an oral, once-daily MEK inhibitor targeting MAPK pathway-driven tumors like pancreatic cancer. For more information, visit www.immuneering.c...
06-16 12:00
Immuneering to Present at the Jefferies Global Healthcare Conference
**Immuneering Corporation to Present at Jefferies Global Healthcare Conference** Immuneering Corporation, a clinical-stage oncology company focused on developing effective and well-tolerated cancer therapies, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The presentation will include a company overview, pipeline updates, and business strategy discussions. Key executives, including CEO Ben Zeskind, CMO Igor Matushan...
05-29 12:00
